Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

Delayed Graft Function Clinical Trial

Official title:

A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01794663
• Other study ID #: OPN305-102
• Secondary ID: 2012-001455-39
• Status: Completed
• Phase: Phase 2
• First received: February 13, 2013
• Last updated: February 15, 2017
• Start date: October 2012
• Est. completion date: June 30, 2016

Study information

• Verified date: February 2017
• Source: Opsona Therapeutics Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not function immediately. If the delay in function means that dialysis is needed in the first 7 days after the transplantation then this is known as delayed graft function or dDGF. Also delayed graft function that does not require dialysis but is present because the serum creatinine does not fall sufficiently is known as functional delayed graft function or fDGF. This problem is often due to an excessive inflammatory reaction to not having had a blood supply between the time of donation and transplant.

OPN-305 is a monoclonal antibody that blocks Toll-like Receptor 2 which is thought to be partly responsible for increasing the risk of this inflammation. It is hoped that the effects of the inflammation will be reduced and therefore prevent dDGF and fDGF from occurring.

The purpose of the study is to explore how effective OPN-305 is in preventing dDGF and fDGF as well as improving other measures of kidney function and the overall safety of the antibody. In the first part of the study, each patient received an Infusion of one of three possible doses of OPN-305 or a placebo and in the second part the most suitable dose of OPN-305 and a placebo would be used. The purpose of this second part of the study is to find out if a dose of OPN-305 which has already been tested in an earlier part of this study can prevent kidney graft dysfunction. For the purposes of this study, kidney function will be assessed using the composite of delayed graft function (dDGF) because dialysis is necessary in the first 7 days and functional delayed graft function that does not require dialysis but is present because the serum creatinine, a key measure of renal function, does not fall sufficiently (fDGF) in the first 7 days post-transplant.

Protocol OPN305-103 follows out to 12 months post-transplant the clinical status and graft function of patients who have completed the 6-month post-transplant period under Part A or Part B of OPN305-102.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 252
• Est. completion date: June 30, 2016
• Est. primary completion date: June 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

INCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS

• First or second renal transplant recipient - for second renal transplantations;

• The second transplant should NOT be due to rejection

• Panel Reactive Antibody (PRA) should be <10%

• Minimum 3 months since the loss of the first transplanted kidney

• Dialysis-dependent at the time of transplantation as documented by:

• Requirement for at least 2 dialysis sessions/week in the 56 days before transplantation

INCLUSION CRITERIA FOR DONOR KIDNEY:

• The donor kidney must be considered compatible according to local transplant guidelines

• An ECD donor defined as:

o Extended Criteria Donor defined as:

• Donor =60 years of age

• Donor 50-59 years of age with two of three of the following criteria present:

• Death due to cerebrovascular accident

• Pre-existing history of systemic hypertension

• Terminal creatinine > 1.5mg/dL (132.6 µmol/L)

• Kidney allograft maintained in cold storage with or without machine perfusion

Exclusion Criteria

EXCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS:

• Use of an investigational drug in the 30 days before Study Day 1

• Participation in any other research

• Known hypersensitivity to human monoclonal antibodies or any of the study-drug excipients

• Previous hypersensitivity to basiliximab or anti-thymocyte globulin (ATG)

• History or known HIV, HBV, or HCV-positive

• History of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin or cervical intraepithelial neoplasia

• Scheduled to undergo multi-organ transplantation

• Planned dual kidney transplantation

• Presence of clinically significant infections requiring continued therapy

• Active tuberculosis

• Existence of any surgical or medical condition, other than the current transplantation which, in the opinion of the investigator, might significantly alter the distribution, metabolism or excretion of study medication

• Presence of uncontrolled diabetes mellitus.

• Current drug and/or alcohol abuse

• History or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation

• Lactating or pregnant woman

• Patient institutionalized by administrative or court order

EXCLUSION CRITERIA FOR ALL DONOR KIDNEYS

• DCD or SCD donor kidney

• Terminal creatinine >3mg/dL

• Donor who is known to have received an investigational drug for I-R injury or graft rejection (immunosuppressant) in the 48h before organ recovery

• Participation in any other research (drug or non-drug)

• Kidney donor <5 years of age or <20kg body weight

• Living donor allograft

• HLA or ABO incompatible kidney as defined by a negative cytotoxic crossmatch

• Donor institutionalized by administrative or court order

Related Conditions & MeSH terms

• Delayed Graft Function

Intervention

Drug:
• OPN-305
Intravenous infusion for 1 hour at start of transplant procedure
• Placebo
Intravenous infusion for 1 hour at start of transplant procedure

Locations

Country	Name	City	State
Austria	Research Site	Linz
Belgium	Research Site	Brussels
Belgium	Research Site	Gent
Belgium	Research Site	Leuven
Belgium	Research Site	Liege
Czech Republic	Research Site	Praha
France	Research Site	Bordeaux
France	Research Site	Paris
France	Research Site	Toulouse
Germany	Research Site	Berlin
Germany	Research Site	Berlin
Germany	Research Site	Bochum
Germany	Research Site	Bonn
Germany	Research Site	Erlangen
Germany	Research Site	Heidelberg
Germany	Research Site	Koln
Germany	Research Site	Mannheim
Germany	Research Site	Munster
Germany	Research Site	Tubingen
Netherlands	Research Site	Groningen
Netherlands	Research Site	Leiden
Netherlands	Research Site	Nijmegen
Netherlands	Research Site	Rotterdam
Poland	Research Site	Bydgoszcz
Poland	Research Site	Lodz
Poland	Research Site	Szczecin
Poland	Research Site	Warsaw
Poland	Research Site	Warszawa
Spain	Research Site	Barcelona
Spain	Research Site	Barcelona
Spain	Research Site	Barcelona
Spain	Research Site	Madrid
Spain	Research Site	Santander
Switzerland	Research Site	Zurich
United Kingdom	Research Site	London
United Kingdom	Research Site	Newcastle upon Tyne
United States	Research Site	Bronx	New York
United States	Research Site	Charleston	South Carolina
United States	Research Site	Chicago	Illinois
United States	Research Site	Dallas	Texas
United States	Research Site	Fort Worth	Texas
United States	Research Site	Harrisburg	Pennsylvania
United States	Research Site	Livingston	New Jersey
United States	Research Site	Los Angeles	California
United States	Research Site	New Orleans	Louisiana
United States	Research Site	New Orleans	Louisiana
United States	Research Site	New York	New York
United States	Research Site	Richmond	Virginia
United States	Research Site	Tampa	Florida
United States	Research Site	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Opsona Therapeutics Ltd.

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Czech Republic,  France,  Germany,  Netherlands,  Poland,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of Early Graft Function EGF	Initiation of dialysis in the first 7 days following renal transplantation and failure of serum creatinine to decrease by at least 10% daily on 3 successive days during the first week post transplantation	First 7 days following renal transplantation
Secondary	Creatinine at 7 and 14 days and at 1, 3 and 6 months	Measure of creatinine at 7 and 14 days and at 1, 3 and 6 months	7 and 14 days and at 1, 3 and 6 months
Secondary	Cystatin C at 7 and 14 days and at 1, 3 and 6 months	Measure of Cystatin C at 7 and 14 days and at 1, 3 and 6 months	7 and 14 days and at 1, 3 and 6 months
Secondary	Symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months	Measure of symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months	7 and 14 days and at 1, 3 and 6 months
Secondary	Incidence of slow graft function	Slow graft function to be assessed over first 5 days post-transplant	5 days post-transplant
Secondary	Serum creatinine over time	Measure of Serum creatinine over time	over the duration of follow-up
Secondary	Composite endpoint	Components of the composite endpoint are: Incidence of biopsy-proven kidney allograft rejection (biopsies will be done on a for-cause basis only); Graft loss; Reports of patient death(s); Patients lost to follow-up	6 months
Secondary	Time to biopsy-proven kidney allograft rejection	Time to biopsy-proven kidney allograft rejection	6 months
Secondary	Time to first dialysis or functional delayed graft function and delayed graft function duration	Duration of DGF is defined as either: Time from transplantation to time of completion of final dialysis for DGF; Time from transplantation to time when creatinine starts to fall by at least 10% without dialysis	30 days
Secondary	Blood and urine biomarkers for acute kidney injury (AKI)	Serum NGAL, urinary NGAL, a-GST, p-GST, KIM-1 and IL-18	days 2, 7, 14, 28, 90 and 180
Secondary	Duration of initial hospitalization	Duration of initial hospitalization	6 months
Secondary	Duration of subsequent readmissions	Duration of subsequent readmissions	6 months
Secondary	Reason for subsequent readmissions	Reason for subsequent readmissions	6 months
Secondary	Number of Adverse events (AEs)	Number of Adverse events (AEs)	6 months
Secondary	Nature of Adverse events (AEs)	Nature of Adverse events (AEs)	6 months
Secondary	Incidence of infections	Incidence of infections by category and organism	6 months
Secondary	Rate of primary non-function (permanent lack of function of the allograft)		6 months
Secondary	Number of dialysis sessions between 0 and 30 days post-transplantation	Number of dialysis sessions between 0 and 30 days post-transplantation	30 days